Aude De Gassart
Epalinges, VD 1066, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling.
Journal: Cell reports
Published: February 14, 2024
The protease DDI2 regulates NRF1 activation in response to cadmium toxicity.
Journal: iScience
Published: April 20, 2022
The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
Journal: Cell death & disease
Published: December 14, 2021
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.
Journal: Science translational medicine
Published: October 20, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells.
Journal: Cell reports
Published: April 03, 2020
MARCH9-mediated ubiquitination regulates MHC I export from the TGN.
Journal: Immunology and cell biology
Published: April 25, 2017
Translating the anticancer properties of eEF2K.
Journal: Cell cycle (Georgetown, Tex.)
Published: November 11, 2016
AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 28, 2016
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
Journal: EMBO reports
Published: February 11, 2016
An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 31, 2015
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 27, 2015
Last Updated: 09/26/2026